MARKET

BIO

BIO

Bio Rad Labs Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

502.34
+7.34
+1.48%
After Hours: 502.34 0 0.00% 16:30 07/01 EDT
OPEN
494.87
PREV CLOSE
495.00
HIGH
503.48
LOW
492.72
VOLUME
116.82K
TURNOVER
0
52 WEEK HIGH
832.70
52 WEEK LOW
462.61
MARKET CAP
15.04B
P/E (TTM)
-103.0356
1D
5D
1M
3M
1Y
5Y
Investors are Watching These 10 Biotech Stocks
In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soarin...
Insider Monkey · 4d ago
Bio-Rad Publishes Corporate Sustainability Report
HERCULES, Calif., June 27, 2022--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its inaugural corporate sustainability report.
Business Wire · 4d ago
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Simply Wall St. · 06/20 10:22
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Zacks · 06/17 16:38
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.
Zacks · 06/16 13:47
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Zacks · 06/06 15:03
Why Is NuVasive (NUVA) Up 6.3% Since Last Earnings Report?
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/03 15:31
Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.
Zacks · 06/03 14:26
More
No Data
Learn about the latest financial forecast of BIO. Analyze the recent business situations of Bio Rad Labs Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BIO stock price target is 711.67 with a high estimate of 750.00 and a low estimate of 685.00.
High750.00
Average711.67
Low685.00
Current 502.34
EPS
Actual
Estimate
1.242.473.714.94
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 689
Institutional Holdings: 21.17M
% Owned: 70.72%
Shares Outstanding: 29.94M
TypeInstitutionsShares
Increased
184
1.72M
New
64
434.56K
Decreased
184
1.76M
Sold Out
78
313.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.13%
Healthcare Equipment & Supplies
+1.92%
Key Executives
Chairman/President/Chief Executive Officer/Director
Norman Schwartz
Chief Financial Officer/Executive Vice President
Ilan Daskal
Chief Operating Officer/Executive Vice President
Andrew Last
Executive Vice President/General Counsel/Secretary
Timothy Ernst
Executive Vice President
Michael Crowley
Executive Vice President
Simon May
Executive Vice President
Dara Wright
Lead Director/Independent Director
Gregory Hinckley
Independent Director
Jeffrey Edwards
Independent Director
Melinda Litherland
Independent Director
Arnold Pinkston
No Data
No Data
About BIO
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. Its segments include Life Science and Clinical Diagnostics. Its Life Science segment markets and develops, manufactures and markets approximately 9,000 reagents, apparatus and laboratory instruments that serve a global customer base. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Its Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. It supplies approximately 3,000 different products that cover over 300 clinical diagnostic tests to the in vitro diagnostics (IVD) test market.

Webull offers kinds of Bio-Rad Laboratories, Inc. stock information, including NYSE:BIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIO stock methods without spending real money on the virtual paper trading platform.